Table 4. . Vemurafenib adverse events reported from the BRIM III trial.
| Adverse event | All grades (%) | Grade 3 (%) | Grade 4 (%) |
|---|---|---|---|
| Dermatologic | |||
| Rash | 37 | 8 | – |
| Photosensitivity reaction | 33 | 3 | – |
| Alopecia | 45 | <1 | – |
| Muscoloskeletal arthralgia | 53 | 4 | – |
| Gastrointestinal | |||
| Nausea | 35 | 2 | – |
| Vomiting | 18 | 1 | – |
| Diarrhea | 28 | <1 | – |
| Constipation | 12 | <1 | – |
| Secondary malignancies | |||
| Skin papilloma | 21 | <1 | – |
| Squamous cell skin cancer | 24 | 22 | – |
| Keratoacanthoma | 11 | 10 | – |
| Other | |||
| Fatigue | 38 | 2 | – |
Data taken from [16] and product monograph ZELBORAF Vemurafenib Roche Canada, 19 December 2013.